MedPage Today on MSN2d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's Drug
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
‘Miracle’ Alzheimer’s drug ‘triggers deadly brain bleeds in up to a third’, new study finds
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
Fresh warning over £60K 'miracle' Alzheimer's drug as study finds it could trigger brain bleeds in up to a third
A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.
pharmaphorum4d
Lilly files Alzheimer's drug donanemab as Cortexyme rival fails trial
Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...
Zacks Investment Research on MSN3d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
GlobalData on MSN6d
UK’s pricing watchdog rejects Alzheimer treatments for the second time
The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
pharmaphorum4d
FDA blocks early nod for Lilly's Alzheimer's drug donanemab
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...
Pharmaceutical Technology on MSN3d
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...